We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dupilumab therapy following JAK inhibitor withdrawal in moderate–severe atopic dermatitis.
- Authors
Kiely, Lisa; O'Connor, Cathal; Murphy, Michelle
- Abstract
The advent of janus kinase inhibitors (JAKi) and targeted biologics is revolutionizing the treatment of recalcitrant atopic dermatitis (AD).1 JAKi have been shown to impair IL-4- and IL-13-dependent differentiation of T SB H sb 2 cells, improve skin barrier function, and suppress itch.2 Dupilumab inhibits IL-4 and IL-13 signaling via their shared IL-4 subunit, suppressing the release of proinflammatory cytokines, chemokines, and immunoglobulin E.3 However, little is known about response to biologic therapy following JAKi failure or withdrawal.4 We present three patients who had treatment with upadacitinib/tofacitinib withdrawn but achieved disease remission with dupilumab. This case series supports the use of dupilumab in patients with moderate-severe AD who require withdrawal of JAKi therapy. Dupilumab therapy following JAK inhibitor withdrawal in moderate-severe atopic dermatitis.
- Subjects
ATOPIC dermatitis; DUPILUMAB; SCABIES; THYMIC stromal lymphopoietin; LYMPHOPENIA; HERPES zoster
- Publication
Dermatologic Therapy, 2022, Vol 35, Issue 10, p1
- ISSN
1396-0296
- Publication type
Article
- DOI
10.1111/dth.15750